NeurAxis, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NRXS research report →
Companyneuraxis.com
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics.
- CEO
- Brian Carrico
- IPO
- 2023
- Employees
- 21
- HQ
- Carmel, IN, US
Price Chart
Valuation
- Market Cap
- $89.79M
- P/E
- -10.90
- P/S
- 20.97
- P/B
- 13.81
- EV/EBITDA
- -11.61
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 85.01%
- Op Margin
- -169.93%
- Net Margin
- -170.11%
- ROE
- -185.74%
- ROIC
- -119.25%
Growth & Income
- Revenue
- $3.57M · 32.89%
- Net Income
- $-7,800,555 · 5.35%
- EPS
- $-0.95 · 22.13%
- Op Income
- $-7,829,908
- FCF YoY
- -5.52%
Performance & Tape
- 52W High
- $9.33
- 52W Low
- $2.20
- 50D MA
- $7.44
- 200D MA
- $4.44
- Beta
- 1.48
- Avg Volume
- 195.23K
Get TickerSpark's AI analysis on NRXS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 28, 26 | Aharon Gil | other | 221,917 |
| Apr 28, 26 | Aharon Gil | other | 12,304 |
| Apr 1, 26 | Henrichs Timothy Robert | buy | 7,593 |
| Apr 1, 26 | Carrico Thomas Joeseph | buy | 667 |
| Apr 1, 26 | Carrico Brian Allen | buy | 8,060 |
| Jan 22, 26 | Miranda Adrian | other | 47,569 |
| Jan 22, 26 | Watkins Bradley Mitchell | other | 21,598 |
| Jan 22, 26 | Keyser Jane Elizabeth | other | 21,598 |
| Jan 22, 26 | Henrichs Timothy Robert | other | 75,231 |
| Jan 22, 26 | Carrico Thomas Joeseph | other | 47,569 |
Our NRXS Coverage
We haven't published any research on NRXS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NRXS Report →